title: [Are we ready to prescribe a polypill to our patients?].
abstract: The all-in-one pill combination (Polypill) of several active components used in primary prevention of cardiovascular disease was a decade ago purposed to reduce the cardiovascular burden by more than 80%. This Polypill could be approved before 2013 in United States. Although controversed, it could answer to the worried situation even observed in Switzerland: the adherence to secondary prevention treatments is clearly insufficient and the cardiovascular events remain in the first row of death's causes. This abstract summarize the results from interventional studies who tried to valid this concept as well as the main stakes to be assessed on the medical side before to consider such a similar approach in Switzerland.
authors.affiliation: Service de médecine interne, Département des laboratoires, CHUV, 1011 Lausanne. Julien.Castioni@chuv.ch
authors.forename: J
authors.initials: J
authors.lastname: Castioni
authors.forename: V
authors.initials: V
authors.lastname: Mooser
authors.forename: G
authors.initials: G
authors.lastname: Waeber
mesh_terms: D002318:Cardiovascular Diseases / Q000517:prevention & control*; D004338:Drug Combinations; D006801:Humans; D011322:Primary Prevention; D016032:Randomized Controlled Trials as Topic
chemical_list: D004338:Drug Combinations